CClinicalTrials.gg
Status unknownNCT03690934Updated Nov 14, 2018

Treatment of Transsphicteric Fistula-in-ano by Method of Laser Thermoobliteration(FiLaC™).

An interventional study of Fistula-tract laser closure (FiLAC™) and Monopolar coagulation of fistulous tract in Anal Fistula, sponsored by State Scientific Centre of Coloproctology, Russian Federation. Status unknown at 1 site in Russian Federation. Open to participants aged 18 Years to 90 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-11-14.

Sponsored by State Scientific Centre of Coloproctology, Russian Federation · Not applicable, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Oct 2018), so the status shown — last known as Recruiting — may be out of date.

From the registry’s dates

  • Registered 10 months after the study started (first participant enrolled Oct 2017, registered Sep 2018).
Phase
Not applicable
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years to 90 Years
Sex
All
01

Study summary

This is a randomized, controlled, parallel study to compare the results of treatment for patients with transsphincteric fistulas-in-ano.

Read the detailed description

We are planning to eroll 120 patients in this study,the duration of the stady be 3 years. Each of two groups will include 60 people. Pationts in the first group will be assigned to get treatment of the fistula-in-ano by laser thermo-obliteration (FiLAC™), patietns of the second group will forego monopolar coagulation of the fistulas tract with suturing the internal fistulas opening.

02

Conditions studied

  • Anal Fistula
03

In context

Rectal Fistula

189 studies on the registry are indexed under Rectal Fistula; 41 are open to participants now.

This study's planned enrollment of 120 is above the median of 68 across 130 interventional studies indexed under Rectal Fistula.

Browse Rectal Fistula studies →

Lead sponsor

State Scientific Centre of Coloproctology, Russian Federation is the lead sponsor of 25 studies on the registry; 6 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  1. Informed consent to the study;
  2. Patients with high transsphincteric fistula (>1/3), suprasphincteric fistula whithout abscesses;
  3. The presence of a formed fistulous tract > 2 cm in length.

Exclusion criteria

Exclusion Criteria:

  1. Suprasphincteric fistula with abscesses or infiltrates;
  2. Extrasphincteric fistula;
  3. Length of fistula tract \< 2 cm;
  4. The presence of sever scars in the region of internal fistula opening, wide fistula opening > 5 mm;
  5. Crohn's fistulae
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    Fistula-tract laser closure (FiLAC™)

    The treatment technique consists of laser coagulation of fistulous tract walls with a diode laser with a wavelength of 1470 nm, which leads to thermo-obliteration of the fistulous tract.

    Procedure: Fistula-tract laser closure (FiLAC™)

  • Active comparator
    Fistula monopolar cogulation

    The treatment technicque consists of monopolar coagulation of fistulous tract walls with suturing the internal fistulas opening.

    Procedure: Monopolar coagulation of fistulous tract

Interventions

  • ProcedureFistula-tract laser closure (FiLAC™)

    The procedure was performed with a diode laser platform emitting laser energy of 15 W at a wavelength of 1470 nm by means of a radial fiber. For obliteration, the fistula track is treated with a continuous slow retraction of the laser fibre withdrawn at a rate of approximately 1 cm per 2-3s.

  • ProcedureMonopolar coagulation of fistulous tract

    The procedure was performed with a monopolar coagulator platform emitting monopolar coagulation. For obliteration, the fistula track is treated with a continuous slow retraction of the monopolar energy with suturing the internal fistulas opening.

06

What researchers measure

Primary outcomes

  1. Rate of healing

    healing

    Time frame: 60 days

07

Study locations

1 of 1 sites recruiting
  • State Scientific Centre of Coloproctology
    Moscow, 123423, Russian Federation
    • Ivan Kostarev, MD · Contact
    Recruiting
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 14, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03690934
Lead sponsor
State Scientific Centre of Coloproctology, Russian Federation
Responsible party
Sponsor
First posted
Oct 1, 2018
Start date
Oct 23, 2017
Primary completion
Aug 31, 2020 (estimated)
Completion
Aug 31, 2020 (estimated)
Last update
Nov 14, 2018

Study contacts

Ivan Kostarev, MD
Contact
djovani_80@mail.ru
+7-499-199-63-98

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Oct 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion